Plerixafor

Drug Profile

Plerixafor

Alternative Names: AMD 3100; JM 3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Genzyme Corporation; Memorial Sloan-Kettering Cancer Center; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Chronic lymphocytic leukaemia; Glioma; Myocardial infarction; Sickle cell anaemia
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in France (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy) in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Second-line therapy or greater) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top